These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Detection of WT1 expression in bone marrow of acute leukemia patients with real-time quantitative RT-PCR]. Gu WY; Chen ZX; Cao XS; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J Zhonghua Xue Ye Xue Za Zhi; 2004 Dec; 25(12):728-31. PubMed ID: 15730716 [TBL] [Abstract][Full Text] [Related]
27. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission. Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332 [TBL] [Abstract][Full Text] [Related]
28. Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia. Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH Biol Blood Marrow Transplant; 2013 Jun; 19(6):958-66. PubMed ID: 23542687 [TBL] [Abstract][Full Text] [Related]
29. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. Lapillonne H; Renneville A; Auvrignon A; Flamant C; Blaise A; Perot C; Lai JL; Ballerini P; Mazingue F; Fasola S; Dehée A; Bellman F; Adam M; Labopin M; Douay L; Leverger G; Preudhomme C; Landman-Parker J J Clin Oncol; 2006 Apr; 24(10):1507-15. PubMed ID: 16575000 [TBL] [Abstract][Full Text] [Related]
30. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement. Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121 [TBL] [Abstract][Full Text] [Related]
31. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia. Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900 [TBL] [Abstract][Full Text] [Related]
32. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Perea G; Lasa A; Aventín A; Domingo A; Villamor N; Queipo de Llano MP; Llorente A; Juncà J; Palacios C; Fernández C; Gallart M; Font L; Tormo M; Florensa L; Bargay J; Martí JM; Vivancos P; Torres P; Berlanga JJ; Badell I; Brunet S; Sierra J; Nomdedéu JF; Leukemia; 2006 Jan; 20(1):87-94. PubMed ID: 16281071 [TBL] [Abstract][Full Text] [Related]
33. Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants. Siehl JM; Reinwald M; Heufelder K; Menssen HD; Keilholz U; Thiel E Ann Hematol; 2004 Dec; 83(12):745-50. PubMed ID: 15340762 [TBL] [Abstract][Full Text] [Related]
34. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335 [TBL] [Abstract][Full Text] [Related]
35. Clinical significance of minimal residual disease in childhood acute myeloid leukemia. Miyamura T; Sakata N; Okamura T; Yasui M; Inoue M; Yagi K; Sako M; Komada Y; Matsuyama T; Oda M; Park YD; Kawa K Int J Hematol; 2004 Apr; 79(3):243-9. PubMed ID: 15168592 [TBL] [Abstract][Full Text] [Related]
36. The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia. Karakas T; Miething CC; Maurer U; Weidmann E; Ackermann H; Hoelzer D; Bergmann L Leukemia; 2002 May; 16(5):846-54. PubMed ID: 11986946 [TBL] [Abstract][Full Text] [Related]
37. [Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients]. Qin YZ; Ruan GR; Li JL; Fu JY; Chang Y; Wang H; Li LD; Liu YR; Chen SS Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):649-52. PubMed ID: 16620548 [TBL] [Abstract][Full Text] [Related]
38. Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia. Nowakowska-Kopera A; Sacha T; Florek I; Zawada M; Czekalska S; Skotnicki AB Leuk Lymphoma; 2009 Aug; 50(8):1326-32. PubMed ID: 19811333 [TBL] [Abstract][Full Text] [Related]
39. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia. Chen JS; Hsiao CC; Sheen JM; Cheng CN Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885 [TBL] [Abstract][Full Text] [Related]
40. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Cilloni D; Saglio G Acta Haematol; 2004; 112(1-2):79-84. PubMed ID: 15179007 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]